<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00825929</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF 08.02</org_study_id>
    <nct_id>NCT00825929</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.</brief_title>
  <acronym>PANNA</acronym>
  <official_title>Study on Pharmacokinetics of Newly Developed ANtiretroviral Agents in HIV-infected pregNAnt Women (PANNA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PENTA Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Due to the potential for pregnancy-induced changes in the pharmacokinetics of medication, one
      cannot assume that the currently licensed doses of the medication to be tested under this
      protocol lead to adequate exposure in an HIV-infected pregnant woman. For the agents under
      study no or limited pharmacokinetic data during pregnancy are available. As the changes in
      pharmacokinetics during pregnancy are most prominent in the third trimester a pharmacokinetic
      curve will be recorded in the third trimester after attaining steady state.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following agents will be studied:

      Etravirine, Intelence, TMC125; Emtricitabine, Emtriva or FTC; Tenofovir, Viread, TDF;
      Atazanavir, Reyataz; Fosamprenavir, Telzir, FPV; Darunavir, Prezista, TMC114; Tipranavir,
      Aptivus, TPV; Indinavir, Crixivan; abacavir; raltegravir, Isentress; Enfuvirtide, Fuzeon;
      Maraviroc, Celsentri; dolutegravir; elvitegravir/cobicistat; rilpivirine, TAF,
      darunavir/cobicistat
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations of the compounds during pregnancy compared to the concentrations after delivery</measure>
    <time_frame>PK curve in Week 33 of pregnancy and 4-6 weeks after delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics in the neonate, in case of post-exposure prophylaxis with one of the agents under study.</measure>
    <time_frame>Week 1, 3 and between 4 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of antiretrovirals during pregnancy</measure>
    <time_frame>GA Week 33 until end of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>viral load response and prevention of mother to child transmission of the virus</measure>
    <time_frame>GA Week 3 and at delivery</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">176</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Treated with one of the antiretroviral agents under study, PK parameters during pregnancy will be compared with PK parameters after pregnancy (within the same woman)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma samples will be collected in Week 33 of the pregnancy and at 4-6 weeks after delivery.
      At the following time points samples will be collected: T=0 (prior to dosing), and T=1, 2, 3,
      4, 6, 8, 12 and 24h (24h sample only in case of QD regimen) post-dosing (8 or 9 samples).

      In case the infant needs post-exposure prophylaxis with at least one of the agents sparse PK
      sampling is optional.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected pregnant women using at least one of the following antiretroverial agents:
        Etravirine, Intelence, TMC125; Emtricitabine, Emtriva or FTC; Tenofovir, Viread, TDF;
        Atazanavir, Reyataz; Fosamprenavir, Telzir, FPV; Darunavir, Prezista, TMC114; Tipranavir,
        Aptivus, TPV; Indinavir, Crixivan; Raltegravir, Isentress; Enfuvirtide, Fuzeon; Maraviroc,
        Celsentri; Abacavir; Rilpivirine
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-infected as documented by positive HIV antibody test and confirmed by Western
             Blot.

          -  Subject is at least 18 years of age at screening.

          -  Subject is able and willing to sign the Informed Consent Form prior to screening
             evaluations.

          -  Treated with an HAART regimen containing at least one agent which is mentioned in
             Appendix 1 of the protocol; this agent has been taken for at least 2 weeks before the
             day of first PK curve evaluation.

          -  Duration of pregnancy not longer than 33 weeks at the day of screening

          -  Subject is able to adhere to food intake recommendations.

        Exclusion Criteria:

          -  Relevant history or current condition that might interfere with drug absorption,
             distribution, metabolism or excretion.

          -  Inability to understand the nature and extent of the study and the procedures
             required.

          -  Presence of grade III/IV anemia (i.e. Hb &lt;4.6 mmol/L or &lt;7.4 g/dL)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M Burger, PharmD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Medical Centre Nijmegen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David M Burger, PharmD PhD</last_name>
    <phone>++31 24 3616405</phone>
    <email>dadvid.burger@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angela Colbers, MSc</last_name>
    <phone>++31 24 3616405</phone>
    <email>angela.colbers@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Saint-Pierre University Hospital; Department of Infectious Diseases</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Konopnicki</last_name>
    </contact>
    <investigator>
      <last_name>D Konopnicki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHARITÉ Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharina von Weizsaecker</last_name>
      <email>katharina.weizsaecker@charite.de</email>
    </contact>
    <investigator>
      <last_name>Katharina von Weizsaecker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juergen Rockstroh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gerd Faetkenheuer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johann Wolfgang Goethe-Universität</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anette Haberl</last_name>
      <email>Annette.Haberl@hivcenter.de</email>
    </contact>
    <investigator>
      <last_name>Annette Haberl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Alba</last_name>
    </contact>
    <investigator>
      <last_name>B Kost, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Hospital and UCD</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Lambert</last_name>
      <email>jlambert@mater.ie</email>
    </contact>
    <investigator>
      <last_name>John Lambert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James's Hospital Dublin</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Lyons</last_name>
      <email>FLyons@STJAMES.IE</email>
    </contact>
    <investigator>
      <last_name>Fiona Lyons, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCSS</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>A Antinori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeannine Nellen, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jeannine Nellen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannine Nellen</last_name>
    </contact>
    <investigator>
      <last_name>Jeannine Nellen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andre van der Ven, Md. PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ineke van der Ende, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Elisabeth hospital</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjo van Kasteren</last_name>
    </contact>
    <investigator>
      <last_name>Marjo van Kasteren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Elisabeth Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M van Kasteren</last_name>
    </contact>
    <investigator>
      <last_name>M van Kasteren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol, Badalona</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jose Molto, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves Granada; Médico Adjunto del Servicio de Medicina Interna</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Hidalgo Tenori</last_name>
      <email>chidalgo72@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Carmen Hidalgo Tenori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brighton and Sussex University Hospitals NHS Trust</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Gilleece</last_name>
    </contact>
    <investigator>
      <last_name>Yvonne Gilleece</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C&amp;W Hospital, London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Hawkins, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Middlesex Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Wood</last_name>
    </contact>
    <investigator>
      <last_name>Chris Wood</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Middlesex Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C Wood</last_name>
    </contact>
    <investigator>
      <last_name>C Wood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Mary's Hospital, London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Graham Taylor, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Thomas Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J Fox</last_name>
    </contact>
    <investigator>
      <last_name>J Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. George's Hospital, London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tariq Sadiq, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Switzerland</country>
  </removed_countries>
  <results_reference>
    <citation>Colbers AP, Hawkins DA, Gingelmaier A, Kabeya K, Rockstroh JK, Wyen C, Weizsäcker K, Sadiq ST, Ivanovic J, Giaquinto C, Taylor GP, Moltó J, Burger DM; PANNA network. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS. 2013 Mar 13;27(5):739-48. doi: 10.1097/QAD.0b013e32835c208b.</citation>
    <PMID>23169329</PMID>
  </results_reference>
  <results_reference>
    <citation>Colbers A, Gingelmaier A, van der Ende M, Rijnders B, Burger D. Pharmacokinetics, safety and transplacental passage of rilpivirine in pregnancy: two cases. AIDS. 2014 Jan 14;28(2):288-90. doi: 10.1097/QAD.0000000000000100.</citation>
    <PMID>24413315</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2009</study_first_submitted>
  <study_first_submitted_qc>January 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2009</study_first_posted>
  <last_update_submitted>November 14, 2017</last_update_submitted>
  <last_update_submitted_qc>November 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>pregnancy</keyword>
  <keyword>antiretrovirals</keyword>
  <keyword>neonates</keyword>
  <keyword>HIV</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Retroviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

